CN108064181A - 包含一种或多种群体表位基共序列抗原的hiv疫苗 - Google Patents

包含一种或多种群体表位基共序列抗原的hiv疫苗 Download PDF

Info

Publication number
CN108064181A
CN108064181A CN201580063643.3A CN201580063643A CN108064181A CN 108064181 A CN108064181 A CN 108064181A CN 201580063643 A CN201580063643 A CN 201580063643A CN 108064181 A CN108064181 A CN 108064181A
Authority
CN
China
Prior art keywords
vaccine
epitope
seq
antigen
population
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201580063643.3A
Other languages
English (en)
Chinese (zh)
Inventor
埃里克·布鲁宁
克劳斯·弗鲁赫
路易斯·皮克尔
贝蒂·T·M·科贝尔
詹姆斯·泰勒
埃米莉·马歇尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cuide National Security Co ltd
Oregon Health and Science University
Vir Biotechnology Inc
Original Assignee
Vill Biotechnology Co Ltd
Oregon Health and Science University
Los Alamos National Security LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vill Biotechnology Co Ltd, Oregon Health and Science University, Los Alamos National Security LLC filed Critical Vill Biotechnology Co Ltd
Publication of CN108064181A publication Critical patent/CN108064181A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C12N15/867—Retroviral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16111—Cytomegalovirus, e.g. human herpesvirus 5
    • C12N2710/16141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Oncology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201580063643.3A 2014-10-03 2015-10-05 包含一种或多种群体表位基共序列抗原的hiv疫苗 Pending CN108064181A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462059497P 2014-10-03 2014-10-03
US201462059506P 2014-10-03 2014-10-03
US62/059,506 2014-10-03
US62/059,497 2014-10-03
PCT/US2015/054067 WO2016054654A1 (en) 2014-10-03 2015-10-05 Hiv vaccines comprising one or more population episensus antigens

Publications (1)

Publication Number Publication Date
CN108064181A true CN108064181A (zh) 2018-05-22

Family

ID=55631703

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201580063643.3A Pending CN108064181A (zh) 2014-10-03 2015-10-05 包含一种或多种群体表位基共序列抗原的hiv疫苗

Country Status (16)

Country Link
US (3) US10894078B2 (https=)
EP (1) EP3200878B1 (https=)
JP (3) JP2017531693A (https=)
KR (1) KR102633096B1 (https=)
CN (1) CN108064181A (https=)
AU (2) AU2015327797A1 (https=)
CA (1) CA2963573C (https=)
EA (1) EA201790680A1 (https=)
HK (1) HK1254806A1 (https=)
IL (1) IL251469B2 (https=)
MA (1) MA40783A (https=)
MX (3) MX391149B (https=)
SG (1) SG11201702729YA (https=)
UA (1) UA126890C2 (https=)
WO (1) WO2016054654A1 (https=)
ZA (1) ZA202206809B (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12053517B2 (en) 2021-01-14 2024-08-06 Gilead Sciences, Inc. HIV vaccines and methods of using
TWI921717B (zh) 2021-01-14 2026-04-11 美商基利科學股份有限公司 Hiv疫苗及使用方法

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
EP3319631A4 (en) 2015-07-08 2019-01-09 American Gene Technologies International Inc. HIV PREMUNICATION AND IMMUNOTHERAPY
WO2017139065A1 (en) 2016-02-08 2017-08-17 American Gene Technologies International Inc. Hiv vaccination and immunotherapy
AU2017292582C1 (en) 2016-07-08 2021-11-11 American Gene Technologies International Inc. HIV pre-immunization and immunotherapy
WO2020243485A1 (en) * 2019-05-29 2020-12-03 Massachusetts Institute Of Technology Hiv-1 specific immunogen compositions and methods of use
KR20240137107A (ko) 2019-07-16 2024-09-19 길리애드 사이언시즈, 인코포레이티드 Hiv 백신, 및 이의 제조 및 사용 방법
MX2022002270A (es) 2019-08-29 2022-03-22 Vir Biotechnology Inc Vacunas contra el virus de la hepatitis b.
JP2024534189A (ja) 2021-08-31 2024-09-18 ヴィア・バイオテクノロジー・インコーポレイテッド 組換えｈｃｍｖベクター及びその使用
TW202436326A (zh) * 2023-02-13 2024-09-16 長怡 王 包含hiv th/ctl 抗原決定位胜肽的疫苗用於預防及治療hiv感染及aids患者
CN116524994B (zh) * 2023-02-20 2026-01-30 中国科学院天津工业生物技术研究所 一种基于贪婪算法的菌株构建排程设计方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101969996A (zh) * 2005-08-23 2011-02-09 加利福尼亚大学董事会 多价疫苗
WO2011143650A2 (en) * 2010-05-14 2011-11-17 Oregon Health & Science University Recombinant hcmv and rhcmv vectors and uses thereof
US20120076812A1 (en) * 2008-11-18 2012-03-29 Barouch Dan H Antiviral vaccines with improved cellular immunogenicity
US20120135032A1 (en) * 2009-10-08 2012-05-31 Bavarian Nordic A/S Generation of a broad t-cell response in humans against hiv
WO2014138209A1 (en) * 2013-03-05 2014-09-12 Oregon Health & Science University Cytomegalovirus vectors enabling control of t cell targeting

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI116851B (fi) * 2001-05-03 2006-03-15 Fit Biotech Oyj Plc Ilmentämisvektori, sen käyttöjä ja menetelmä sen valmistamiseksi sekä sitä sisältäviä tuotteita
MXPA04002631A (es) * 2001-09-20 2004-07-08 Glaxo Group Ltd Vacunas de adn optimizadas por codon gag-vih.
AUPR842501A0 (en) 2001-10-23 2001-11-15 Epipop Pty Ltd A method for identification and development of therapeutic agents
US20030190308A1 (en) * 2002-03-19 2003-10-09 Braun Ralph P. Adjuvant
GB0225788D0 (en) * 2002-11-05 2002-12-11 Glaxo Group Ltd Vaccine
US20070054262A1 (en) * 2003-03-28 2007-03-08 Baker Denise M Methods of identifying optimal variants of peptide epitopes
AU2011203095A1 (en) 2003-09-17 2011-07-21 Duke University Consensus/Ancestral Immunogens
BRPI0414443A (pt) * 2003-09-17 2006-11-21 Univ Duke imunógenos consensuais/ancestrais
EA012066B1 (ru) 2003-10-10 2009-08-28 Паудерджект Вэксинс, Инк. Способ, вызывающий т-клеточный ответ
EP2497831B1 (en) 2004-05-25 2014-07-16 Oregon Health and Science University TB vaccination using HCMV-based vaccine vectors
CA3057039C (en) 2006-07-28 2023-02-28 The Trustees Of The University Of Pennsylvania Hiv consensus envelope sequences and methods for using same
US20110123485A1 (en) * 2007-03-27 2011-05-26 President And Fellows Of Harvard College Viral vectors for delivering vaccines for hiv and other infectious diseases
WO2008121282A2 (en) * 2007-03-30 2008-10-09 Merck & Co., Inc. Broadly representative antigen sequences and method for selection
AU2011230619C1 (en) 2010-03-25 2016-06-23 Oregon Health & Science University CMV glycoproteins and recombinant vectors
US8557787B2 (en) 2011-05-13 2013-10-15 The Board Of Trustees Of The Leland Stanford Junior University Diagnostic, prognostic and therapeutic uses of long non-coding RNAs for cancer and regenerative medicine
HUE037408T2 (hu) 2011-06-10 2018-08-28 Univ Oregon Health & Science CMV glikoproteinek és rekombináns vektorok
EP2620446A1 (en) 2012-01-27 2013-07-31 Laboratorios Del Dr. Esteve, S.A. Immunogens for HIV vaccination
EP2820035B1 (en) 2012-03-02 2019-01-09 The Government of the United States of America as represented by The Secretary of the Department of Health and Human Services Method of altering the immundominance hierarchy of hiv gag by dna vaccine expressing conserved regions
SG10201705880QA (en) * 2013-01-07 2017-08-30 Beth Israel Deaconess Medical Ct Inc Stabilized human immunodeficiency virus (hiv) envelope (env) trimer vaccines and methods of using the same
CA2941116A1 (en) 2014-02-28 2015-09-03 Janssen Vaccines & Prevention B.V. Replicating recombinant adenovirus vectors, compositions, and methods of use thereof
CN113528466B (zh) 2014-07-16 2024-12-24 俄勒冈健康与科学大学 包含外源抗原的人巨细胞病毒
CN106999571B (zh) 2014-09-26 2020-10-02 贝斯以色列护理医疗中心有限公司 诱导针对人免疫缺陷病毒感染的保护性免疫性的方法和组合物
MA40783A (fr) 2014-10-03 2017-08-08 Los Alamos Nat Security Llc Vaccins contre le vih comprenant un ou plusieurs antigènes episensus de population
DK3584252T3 (da) 2015-12-15 2021-11-15 Janssen Vaccines & Prevention Bv Human immundefektvirus-antigener, -vektorer, -sammensætninger og fremgangsmåder til anvendelse deraf

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101969996A (zh) * 2005-08-23 2011-02-09 加利福尼亚大学董事会 多价疫苗
US20120076812A1 (en) * 2008-11-18 2012-03-29 Barouch Dan H Antiviral vaccines with improved cellular immunogenicity
US20120135032A1 (en) * 2009-10-08 2012-05-31 Bavarian Nordic A/S Generation of a broad t-cell response in humans against hiv
WO2011143650A2 (en) * 2010-05-14 2011-11-17 Oregon Health & Science University Recombinant hcmv and rhcmv vectors and uses thereof
WO2014138209A1 (en) * 2013-03-05 2014-09-12 Oregon Health & Science University Cytomegalovirus vectors enabling control of t cell targeting

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KORBER,BETTE T. M: "LANL/New Mexico Consortium HIV vaccine design and Analysis", 《LOS ALAMOS NATIONAL LABORATORY》 *
王学林: "《分子药理学》", 30 June 2011, 北京：中国医药科技出版社 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12053517B2 (en) 2021-01-14 2024-08-06 Gilead Sciences, Inc. HIV vaccines and methods of using
TWI921717B (zh) 2021-01-14 2026-04-11 美商基利科學股份有限公司 Hiv疫苗及使用方法
TWI921443B (zh) 2021-01-14 2026-04-11 美商基利科學股份有限公司 Ｈｉｖ疫苗及使用方法

Also Published As

Publication number Publication date
AU2021218141B2 (en) 2024-06-06
CA2963573A1 (en) 2016-04-07
KR102633096B1 (ko) 2024-02-02
ZA202206809B (en) 2023-11-29
JP2021035946A (ja) 2021-03-04
UA126890C2 (uk) 2023-02-22
IL251469B2 (en) 2023-05-01
NZ731173A (en) 2024-04-26
IL251469A0 (en) 2017-05-29
EP3200878A4 (en) 2018-05-30
US20170319679A1 (en) 2017-11-09
EA201790680A1 (ru) 2017-11-30
EP3200878A1 (en) 2017-08-09
JP7441340B2 (ja) 2024-03-06
CA2963573C (en) 2024-02-06
US20210046174A1 (en) 2021-02-18
US11554168B2 (en) 2023-01-17
JP2023059272A (ja) 2023-04-26
SG11201702729YA (en) 2017-04-27
MX391149B (es) 2025-03-21
US10894078B2 (en) 2021-01-19
AU2021218141A1 (en) 2021-09-09
IL251469B1 (en) 2023-01-01
MX2022003663A (es) 2022-04-25
EP3200878B1 (en) 2025-06-04
MX2017004275A (es) 2018-01-17
MX2022003664A (es) 2022-04-25
US11628215B2 (en) 2023-04-18
HK1254806A1 (zh) 2019-07-26
AU2015327797A1 (en) 2017-05-11
MA40783A (fr) 2017-08-08
KR20170122711A (ko) 2017-11-06
JP7212020B2 (ja) 2023-01-24
JP2017531693A (ja) 2017-10-26
BR112017006865A2 (pt) 2017-12-12
WO2016054654A1 (en) 2016-04-07
US20210046175A1 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
AU2021218141B2 (en) HIV vaccines comprising one or more population episensus antigens
US20230165952A1 (en) Betacoronavirus prophylaxis and therapy
Doria-Rose et al. Human immunodeficiency virus type 1 subtype B ancestral envelope protein is functional and elicits neutralizing antibodies in rabbits similar to those elicited by a circulating subtype B envelope
Lu et al. Humoral and cellular immune responses induced by 3a DNA vaccines against severe acute respiratory syndrome (SARS) or SARS-like coronavirus in mice
JP7635208B2 (ja) Ｂ型肝炎ウイルスワクチン
Jafarpour et al. Clustered epitopes within a new poly-epitopic HIV-1 DNA vaccine shows immunogenicity in BALB/c mice
HK1241309A1 (en) Hiv vaccines comprising one or more population episensus antigens
HK1241309B (en) Hiv vaccines comprising one or more population episensus antigens
EA040402B1 (ru) Вакцины против вируса иммунодефицита человека (вич), содержащие один или более эписенсусных (episensus) антигенов для популяции
BR122021016789B1 (pt) Vacinas contra hiv-1 compreendendo um ou mais antígenos epissenso de população, usos das mesmas para proteger um indivíduo de uma infecção por hiv-1, tratar hiv-1 e induzir uma resposta de células t de memória efetoras, bem como polipeptídeo e método para projetar e produzir as ditas vacinas
BR112017006865B1 (pt) Vacina contra hiv-1 compreendendo um ou mais antígenos epissenso de população, uso da mesma para proteger um indivíduo de uma infecção por hiv-1 ou para tratar hiv-1 e polipeptídeo
HK40074198A (en) Hepatitis b virus vaccines
RU2848314C1 (ru) Профилактика и лечение бетакоронавируса
Rhimi et al. Prospective on Different Approaches for Vaccine Development Against COVID-19: past lessons and future challenges
HK40090677A (zh) 流感疫苗
CN102321653A (zh) 人鼠嵌合型cd4质粒及其多抗在抑制hiv感染中的应用

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1254806

Country of ref document: HK

TA01 Transfer of patent application right

Effective date of registration: 20210622

Address after: New Mexico USA

Applicant after: Cuide National Security Co.,Ltd.

Applicant after: Oregon Health & Science University

Applicant after: VIR BIOTECHNOLOGY Inc.

Address before: New Mexico USA

Applicant before: LOS ALAMOS NATIONAL SECURITY, LLC

Applicant before: Oregon Health & Science University

Applicant before: VIR BIOTECHNOLOGY Inc.

TA01 Transfer of patent application right